Jiangsu Hengrui Medicine Co., Ltd.
Clinical trials sponsored by Jiangsu Hengrui Medicine Co., Ltd., explained in plain language.
-
New drug combo trial offers hope for advanced lung cancer patients
Disease control Recruiting nowThis study is testing whether adding SHR2554 tablets to other cancer treatments is safe and effective for people with advanced non-small cell lung cancer. Researchers will enroll 200 adults to see if this combination helps shrink tumors and control the disease. The trial focuses …
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
New cancer drug begins first human tests
Disease control Recruiting nowThis is the first study in people to test a new drug called HRS-7172. It aims to find a safe dose and see how the body processes the drug in 120 adults with advanced solid tumors that have specific genetic changes (RAS mutations or amplifications). The main goal is to check for s…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 21:40 UTC
-
New drug trial aims to help liver patients undergo surgery safely
Disease control Recruiting nowThis study is testing if a drug called Herombopag can safely increase platelet counts in people with chronic liver disease who need elective surgery. Low platelets increase bleeding risk during procedures. The goal is to see if the drug can raise counts enough to avoid needing pl…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New cancer drug seeks to tame tough tumors
Disease control Recruiting nowThis study is testing a new drug called FH-006 for people with advanced solid tumors that have grown despite standard treatments. The main goals are to find a safe and effective dose and to see how well the drug works at controlling the cancer. It is for adults whose cancer has r…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Radioactive drug trial offers new hope for advanced cancer patients
Disease control Recruiting nowThis early-stage trial is testing a new radioactive drug called HRS-6768 in patients with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how the drug moves through and affects the body. Re…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New experimental drug targets advanced cancers with specific marker
Disease control Recruiting nowThis early-stage study is testing an experimental drug called SHR-A1904 in people with advanced solid tumors, specifically gastric, pancreatic, and other cancers that have stopped responding to standard treatments. The main goals are to find the safest and most effective dose, ch…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo trial offers hope for advanced prostate cancer patients
Disease control Recruiting nowThis study is testing whether a new oral drug called HRS-5041, when given alongside other standard prostate cancer treatments, is safe and effective for men with advanced disease. It will involve about 100 male participants to find the best dose and see how well it controls cance…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for advanced lung cancer patients after standard treatments fail
Disease control Recruiting nowThis study is testing a new oral drug, HRS-4508, for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors and control the cancer, while closely monitoring its safety. The trial will enroll…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug combo trial targets advanced cancers with specific mutation
Disease control Recruiting nowThis early-stage trial is testing whether a new drug called HRS-4642, when combined with other cancer treatments, is safe and effective for people with advanced solid tumors that have a specific genetic change (KRAS G12D mutation). The study aims to find the best dose and see if …
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo trial offers hope for advanced stomach cancer patients
Disease control Recruiting nowThis study is testing whether adding a new oral drug called SHR2554 to other cancer treatments is safe and effective for people with advanced stomach cancer that has spread or cannot be removed by surgery. It will involve about 351 adults with this condition. The main goals are t…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New targeted therapy trial offers hope for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether an experimental drug called SHR-A1811 works better than current standard treatments for people with advanced lung cancer that has specific HER2 mutations. Researchers will enroll 300 adults who haven't had previous treatment for their advanced cancer…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New breast cancer drug combo enters human testing
Disease control Recruiting nowThis study is testing a new drug called HRS-6209, given in combination with other treatments, for women with breast cancer. The main goals are to find a safe dose and see if the drug combination shows early signs of helping to control the cancer. The study will enroll about 80 wo…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug combo tested for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing a new drug called FH-006 when given alongside other standard lung cancer treatments. It aims to find the safest and most effective dose and see how well it helps shrink tumors in people with advanced lung cancer that can't be cured with surgery or radiation.…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for tough stomach cancers: testing a powerful Two-Drug combo
Disease control Recruiting nowThis study is for people with advanced stomach or gastroesophageal junction cancer that has continued to grow after their first round of chemotherapy. It aims to see if a new combination of two drugs (camrelizumab and apatinib) can help people live longer than the current standar…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for women with advanced cervical cancer after standard treatments fail
Disease control Recruiting nowThis study is testing an experimental drug called SHR-A1811 for women with advanced cervical cancer that has returned or spread and no longer responds to standard treatments. The trial will enroll 60 participants to see if the drug can shrink tumors and control the cancer. Resear…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New drug enters final testing for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study aims to see if a new drug called SHR2554 works better than an existing drug, chidamide, for adults with a type of blood cancer called PTCL that has come back or hasn't responded to prior treatment. It's a large, late-stage trial where neither the doctors nor the patien…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New drug aims for better control during surgery
Disease control Recruiting nowThis study is testing a new muscle relaxant drug called HRS-9190 for use during surgery. It will be compared to a commonly used drug, rocuronium, to see if it works as well to keep patients safely relaxed during an operation and how quickly its effects wear off afterwards. The go…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New combo therapy trial aims to restore skin color in vitiligo
Disease control Recruiting nowThis study is testing whether a new oral tablet called SHR0302, used alone or with a matching SHR0302 gel, can help restore skin color in adults with non-segmental vitiligo. Researchers will measure changes in the size and appearance of white patches on the face and body over 24 …
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for pancreatic cancer patients in major trial
Disease control Recruiting nowThis large Phase 3 trial is comparing a new combination of cancer drugs against the current standard treatment for advanced pancreatic cancer that has spread. The main goal is to see if the new treatment helps patients live longer. Researchers will enroll 662 adults with newly di…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug targets 'Undruggable' cancer mutation in first human trial
Disease control Recruiting nowThis is the first study in people to test a new drug called HRS-6093, which is designed to target a specific genetic change (KRAS G12D mutation) found in some advanced solid tumors. The main goal is to find a safe dose and understand how the drug moves through the body in about 1…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in people testing a new drug called HRS-2329 for advanced solid tumors that have specific genetic changes called RAS mutations or amplifications. The main goal is to find a safe dose and understand how the drug moves through the body. It will enroll about …
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for men with aggressive prostate cancer
Disease control Recruiting nowThis study is testing whether a new drug called HRS-4357 works better than current standard medications for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 370 participants will be randomly assigned to receive either the new drug…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New breast cancer drug trial aims to shrink tumors before surgery
Disease control Recruiting nowThis study is testing whether a new drug called SHR-A1811 works better than the current standard treatment for shrinking HER2-positive breast tumors before surgery. About 740 women with early or locally advanced breast cancer will receive either the new drug or standard chemother…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for advanced prostate cancer: testing two drug combos
Disease control Recruiting nowThis study is testing whether adding one of two new oral drugs (HS-20093 or SHR2554) to standard hormone therapy helps men with advanced prostate cancer that has spread. It will enroll 218 men to see if these combinations are safe and can better control the cancer by lowering PSA…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for men with spreading prostate cancer
Disease control Recruiting nowThis study is testing a new drug, HRS-1167, combined with standard prostate cancer medications (abiraterone and prednisone) in men whose cancer has spread. The main goals are to find the safest and most effective dose and to see how well the combination works to control the cance…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Head-to-Head prostate cancer drug showdown: which treatment controls cancer better?
Disease control Recruiting nowThis study compares two medications, rezvilutamide and enzalutamide, for men with prostate cancer that has spread but still responds to hormone-blocking therapy. Both drugs will be given alongside standard hormone treatment to see which one better controls cancer growth and cause…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC
-
New drug combo tested for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether a new drug called HRS-4508, when combined with other cancer therapies, can help control advanced lung cancer. It's for people whose cancer has continued to grow despite standard treatments. Researchers will measure how well the combination works and …
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 02, 2026 15:21 UTC
-
New shot aims to block Post-Surgery pain for days
Symptom relief Recruiting nowThis study is testing a new, long-lasting numbing medicine injected near the spine to control pain after minimally invasive lung surgery. Researchers want to see if this special, slow-release formula provides better and longer pain relief than standard options. The trial will inv…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Symptom relief
Last updated Mar 31, 2026 12:11 UTC
-
New shot aims to ease kids' surgery pain for days, cutting need for strong opioids
Symptom relief Recruiting nowThis study is testing a special, long-lasting numbing injection given during surgery to see if it safely controls pain for up to 3 days afterward in children aged 6-17. The main goal is to check for side effects related to the heart or nervous system. Researchers also want to see…
Phase: PHASE4 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC
-
New drug aims to ease the agony of ICU breathing tubes
Symptom relief Recruiting nowThis study is testing a new injection called Tegileridine Fumarate to see if it can safely and effectively manage pain and sedation for 2-3 days in ICU patients who need help breathing from a machine. It will compare the new drug to an existing standard treatment. The goal is to …
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC
-
New sedative tested for safer surgery in kids
Symptom relief Recruiting nowThis study is testing a sedative medicine called remimazolam to see if it is safe and works well for keeping children and teenagers asleep and comfortable during surgery. It will involve 240 young patients who are having planned operations. Researchers will measure how well the s…
Phase: PHASE2, PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Symptom relief
Last updated Mar 27, 2026 12:40 UTC
-
Early test for new diabetes shot begins
Knowledge-focused Recruiting nowThis is an early-stage study to understand how a new injection called SHR-3167 behaves in the body of people with type 2 diabetes. It will measure the drug's levels in the blood over time and check for side effects, including low blood sugar. The goal is to gather basic safety an…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC
-
First human tests begin for new experimental injection
Knowledge-focused Recruiting nowThis is an early-stage study to check if a new injectable drug called HRS-2183 is safe and how it moves through the body. It involves 42 healthy Chinese adults who will receive single or multiple doses. The main goal is to monitor for side effects and measure how the drug is abso…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC